Showing 1 - 3 results of 3 for search 'D. Hochhauser', query time: 0.02s
Refine Results
-
1
-
2
PB2099: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCL by A. Sharp, A. Williams, S. Blagden, R. Plummer, D. Hochhauser, M. G. Krebs, S. Pacey, J. Evans, S. Whelan, S. Nandakumar, S. Rogers, K. L. Jameson, F. G. Basile, J. de Bono, H.-T. Arkenau
Published 2022-06-01
Article -
3
Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans by J. M. Vicencio, R. Evans, R. Green, Z. An, J. Deng, C. Treacy, R. Mustapha, J. Monypenny, C. Costoya, K. Lawler, K. Ng, K. De-Souza, O. Coban, V. Gomez, J. Clancy, S. H. Chen, A. Chalk, F. Wong, P. Gordon, C. Savage, C. Gomes, T. Pan, G. Alfano, L. Dolcetti, J. N. E. Chan, F. Flores-Borja, P. R. Barber, G. Weitsman, D. Sosnowska, E. Capone, S. Iacobelli, D. Hochhauser, J. A. Hartley, M. Parsons, J. N. Arnold, S. Ameer-Beg, S. A. Quezada, Y. Yarden, G. Sala, T. Ng
Published 2022-03-01
Article